prof. siefker-radtke on the ev-103 trial in bladder cancer
Published 4 years ago • 150 plays • Length 0:45Download video MP4
Download video MP3
Similar videos
-
13:47
ev-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
-
2:10
initial ev-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
-
1:07
dr. petrylak on the results of the ev-103 trial in bladder cancer
-
1:54
dr. siefker-radtke on the phase ii study of erdafitinib in patients with urothelial carcinoma
-
2:09
ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
-
1:12
ongoing clinical trials in bladder cancer
-
1:51
dr. siefker-radtke on the treatment of fgfr-altered bladder cancer
-
2:04
unmet need in bladder cancer
-
4:34
optimising treatment for advanced urothelial cancer: combination, maintenance or sequencing?
-
0:53
dr. siefker-radtke on fda approval of durvalumab in bladder cancer
-
0:55
dr. siefker-radtke on fda approval of frontline atezolizumab in bladder cancer
-
2:20
ev-103 cohort k: enfortumab vedotin /- pembro in untreated cis-ineligible patients with muc
-
4:42
arlene siefker-radtke, md, regarding the development of erdafitinib in bladder cancer
-
2:20
toxicity management and monitoring during bladder cancer treatment
-
1:19
dr. siefker-radtke on advancements in small cell urothelial cancer
-
1:28
immune checkpoint inhibitors and sitravatinib in bladder cancer
-
1:06
key trials in bladder cancer from asco gu 2022
-
2:52
enfortumab vedotin in urothelial cancer
-
1:54
targeted therapy effective for patients with advanced bladder cancer and specific gene mutations